Are you familiar with Angioedema Centers of Reference and Excellence (ACARE)? In this episode, our host is joined by Dr Anete Grumach, to celebrate the recent successes of the ACARE network and discuss the future of this exciting initiative.
Perhaps you have already heard about our Journal Club. Perhaps you also are or know a junior physician / PhD student who is interested in participating in the journal club. If so, please read on, and pass the information on
In this episode, our host is joined by Dr Caroline Mann, a urticariologist and sleep expert, who highlights the profound impact of sleep disturbance on quality of life in patients with urticaria and explains what can be done to address this common, but often overlooked aspect of the disease.
In collaboration with Prof. Dr. Marcus Maurer and Prof. Dr. Petra Staubach-Renz, Medthority presents a 30-minute independent session chaired by Marcus Maurer, where the expert panel will explore some of the key learnings from ‘All Things Urticaria’, the UCARE network’s podcast series. The webniar will be hosted live within Medthority on the 28th October 2021
Berlin, 21.09.2021 (GA2LEN UCARE Network). Burning, itching, pain - more than one percent of the world’s population suffers from chronic urticaria (hives) and the number is growing. Unfortunately, this disease still receives too little public attention. The GA²LEN UCARE Network, the Urticaria Network (UNEV) and the German Allergy and Asthma Association (DAAB) have therefore been initiating World...
In this episode, our host is joined by Dr Ivan Chérrez Ojeda, an urticariologist and communication technology enthusiast, to discuss the potential application of telemedicine in the management of patients with chronic urticaria.
Could targeting cytokines produced by autoreactive T cells benefit patients with chronic spontaneous urticaria (CSU)? Professor Marcus Maurer is joined by Professor Elias Toubi to discuss the role of T cells in CSU.
At EAACI 2021 touchIMMUNOLOGY has joined Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.